Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrea Zuckerman

Showing results (1-10 of 15) with videos related to

Pageof 2
Sort By:
Journal of Pediatric and Adolescent Gynecology|December 15, 2016
Clinical Recommendation: VulvovaginitisAndrea Zuckerman, Mary Romano
The American Journal of Geriatric Pharmacotherapy|August 5, 2008
Cardiovascular risk factors and dementiaHoward Fillit, David T Nash, Tatjana Rundek, et al.
Journal of the Cardiometabolic Syndrome|September 6, 2007
Atorvastatin does not induce glomerular or tubular dysfunction even at high dosesMurray Epstein, Elizabeth Leary, Rachel Laskey, et al.
Journal of the American Society of Nephrology : JASN|July 23, 2003
Aldosterone plays a pivotal role in the pathogenesis of thrombotic microangiopathy in SHRSPPraveen N Chander, Ricardo Rocha, Jeffrey Ranaudo, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|February 14, 2009
Focused atorvastatin therapy in managed-care patients with coronary heart disease and CKDMichael J Koren, Michael H Davidson, Daniel J Wilson, et al.
Fertility and Sterility|September 28, 2021
Iconic brands: standing the test of time with a little rebrandingSteven R Lindheim, Samantha M Pfeifer, Beth W Rackow, et al.
Seminars in Arthritis and Rheumatism|April 16, 2016
Effects of tofacitinib and other DMARDs on lipid profiles in rheumatoid arthritis: implications for the rheumatologistChristina Charles-Schoeman, Miguel A Gonzalez-Gay, Irina Kaplan, et al.
Seminars in Arthritis and Rheumatism|July 23, 2016
Cardiovascular safety findings in patients with rheumatoid arthritis treated with tofacitinib, an oral Janus kinase inhibitorChristina Charles-Schoeman, Pierre Wicker, Miguel A Gonzalez-Gay, et al.
Journal of the American College of Cardiology|April 12, 2008
Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) studyJames Shepherd, John J P Kastelein, Vera Bittner, et al.
Clinical Journal of the American Society of Nephrology : CJASN|October 19, 2007
Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: the Treating to New Targets (TNT) studyJames Shepherd, John J P Kastelein, Vera Bittner, et al.
Pageof 2

Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
Journal of Pediatric and Adolescent Gynecology|December 15, 2016
Clinical Recommendation: VulvovaginitisAndrea Zuckerman, Mary Romano
The American Journal of Geriatric Pharmacotherapy|August 5, 2008
Cardiovascular risk factors and dementiaHoward Fillit, David T Nash, Tatjana Rundek, et al.
Journal of the Cardiometabolic Syndrome|September 6, 2007
Atorvastatin does not induce glomerular or tubular dysfunction even at high dosesMurray Epstein, Elizabeth Leary, Rachel Laskey, et al.
Journal of the American Society of Nephrology : JASN|July 23, 2003
Aldosterone plays a pivotal role in the pathogenesis of thrombotic microangiopathy in SHRSPPraveen N Chander, Ricardo Rocha, Jeffrey Ranaudo, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|February 14, 2009
Focused atorvastatin therapy in managed-care patients with coronary heart disease and CKDMichael J Koren, Michael H Davidson, Daniel J Wilson, et al.
Fertility and Sterility|September 28, 2021
Iconic brands: standing the test of time with a little rebrandingSteven R Lindheim, Samantha M Pfeifer, Beth W Rackow, et al.
Seminars in Arthritis and Rheumatism|April 16, 2016
Effects of tofacitinib and other DMARDs on lipid profiles in rheumatoid arthritis: implications for the rheumatologistChristina Charles-Schoeman, Miguel A Gonzalez-Gay, Irina Kaplan, et al.
Seminars in Arthritis and Rheumatism|July 23, 2016
Cardiovascular safety findings in patients with rheumatoid arthritis treated with tofacitinib, an oral Janus kinase inhibitorChristina Charles-Schoeman, Pierre Wicker, Miguel A Gonzalez-Gay, et al.
Journal of the American College of Cardiology|April 12, 2008
Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) studyJames Shepherd, John J P Kastelein, Vera Bittner, et al.
Clinical Journal of the American Society of Nephrology : CJASN|October 19, 2007
Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: the Treating to New Targets (TNT) studyJames Shepherd, John J P Kastelein, Vera Bittner, et al.
Pageof 2